Fenton Caroline, Scott Lesley J
Adis International Limited, Private Bag 65901, Mairangi Bay, Auckland, New Zealand.
CNS Drugs. 2005;19(5):429-44. doi: 10.2165/00023210-200519050-00005.
Risperidone (Risperdal) is an atypical antipsychotic with high affinity for 5-hydroxytryptamine (5-HT)2A, dopamine D2 and alpha1- and alpha2-adrenergic receptors. Risperidone is now approved in the UK and the US for use in bipolar mania. Risperidone < or =6 mg/day, as monotherapy or adjunctive therapy with first-line mood stabilisers, significantly improves moderate and severe bipolar mania and improves global functioning over 3 weeks. Improvements in Young Mania Rating Scale (YMRS) scores in double-blind trials were greater with risperidone than with placebo over 3 weeks, and similar to those with haloperidol over 3 and 12 weeks. Risperidone was reasonably well tolerated. Limited data are available on the combination of risperidone and carbamazepine. Risperidone, as monotherapy or combined therapy with lithium or valproate semisodium, is an effective treatment option in bipolar mania.
利培酮（维思通）是一种非典型抗精神病药物，对5-羟色胺（5-HT）2A、多巴胺D2以及α1和α2肾上腺素能受体具有高亲和力。利培酮目前在英国和美国已被批准用于双相躁狂症。利培酮作为单一疗法或与一线心境稳定剂联合使用，剂量≤6毫克/天，在3周内可显著改善中度和重度双相躁狂症，并改善整体功能。在双盲试验中，利培酮在3周内对青年躁狂评定量表（YMRS）评分的改善比安慰剂更大，在3周和12周时与氟哌啶醇相似。利培酮耐受性较好。关于利培酮与卡马西平联合使用的数据有限。利培酮作为单一疗法或与锂盐或丙戊酸钠联合使用，是双相躁狂症的一种有效治疗选择。
